Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

• Published in: The Journal of clinical investigation Vol. 130; no. 11; pp. 6141 - 6150
• Main Authors: Klein, Sabra L., Pekosz, Andrew, Park, Han-Sol, Ursin, Rebecca L., Shapiro, Janna R., Benner, Sarah E., Littlefield, Kirsten, Kumar, Swetha, Naik, Harnish Mukesh, Betenbaugh, Michael J., Shrestha, Ruchee, Wu, Annie A., Hughes, Robert M., Burgess, Imani, Caturegli, Patricio, Laeyendecker, Oliver, Quinn, Thomas C., Sullivan, David, Shoham, Shmuel, Redd, Andrew D., Bloch, Evan M., Casadevall, Arturo, Tobian, Aaron A.R.
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 01.11.2020
• Subjects: Adult; Age; Age Factors; Aged; Animals; Antibodies; Antibodies, Viral - blood; Antibodies, Viral - immunology; Antibody Formation; Antibody response; Antigen-antibody reactions; Antiviral drugs; Avidity; Betacoronavirus - immunology; Betacoronavirus - metabolism; Biomedical research; Blood Donors; Care and treatment; Chlorocebus aethiops; Convalescence; Convalescent plasma therapy; Coronaviridae; Coronavirus Infections - blood; Coronavirus Infections - immunology; Coronavirus Infections - therapy; Coronaviruses; COVID-19; Demographic aspects; Development and progression; Disease age factors; Enzyme-linked immunosorbent assay; Female; Hospital patients; Hospitalization; Humans; Immune response (humoral); Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunologic research; Infections; Male; Males; Middle Aged; Pandemics; Patient outcomes; Plasma; Pneumonia, Viral - blood; Pneumonia, Viral - immunology; Pneumonia, Viral - therapy; Prediction models; Proteins; Regression analysis; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Sex Factors; Vero Cells; Viral infections; United States; China; COVID-19; Immunoglobulins

Convalescent plasma is a leading treatment for coronavirus disease 2019 (COVID-19), but there is a paucity of data identifying its therapeutic efficacy. Among 126 potential convalescent plasma donors, the humoral immune response was evaluated using a severe acute respiratory syndrome coronavirus 2 (...